Home > Cloud PRWire > Emyria recruits first patient for MDMA-assisted therapy trial

Emyria recruits first patient for MDMA-assisted therapy trial

–News Direct–

Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has recruited the first patient for its Phase 2B MDMA-assisted therapy trial for post-traumatic stress disorder (PTSD).

The EMDMA-001 trial has been designed to assess the safety, efficacy and cost-effectiveness of MDMA-assisted therapy for PTSD.

It aims to generate vital data that will strengthen Emyria's position as a leader in providing psychedelic-assisted therapy within a comprehensive multidisciplinary clinical service.

The news comes soon after Emyria announced it was acquiring the Pax Centre, Australias leading multidisciplinary psychological trauma care service.

It brings a top-tier clinical service into the EMD fold, expanding its capabilities as it develops therapies to meet a burgeoning market.

A report from InsightAce Analytics expects the total addressable market for psychedelic assisted therapies to reach US$8.31 billion by 2028.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/emyria-recruits-first-patient-for-mdma-assisted-therapy-trial-113667941

Emyria Ltd

comtex tracking

COMTEX_436701515/2655/2023-07-11T12:59:49

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Sahyadri Times journalist was involved in the writing and production of this article.